Hepa-Merz

Ornithine Aspartate, the active ingredient in Hepa-Merz, is an ammonia‑lowering agent presented as an oral formulation for oral use. It supports reduction of elevated blood ammonia levels, primarily in patients with liver‑related conditions such as hepatic encephalopathy.

GNH USA supplies Hepa-Merz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Ornithine Aspartate is used to manage conditions associated with elevated ammonia levels, particularly in liver disease.

- Hepatic encephalopathy: helps lower blood ammonia, improving neurological symptoms. - Liver cirrhosis with hyperammonemia: supports ammonia detoxification. - Post‑operative hepatic dysfunction: aids in reducing ammonia accumulation.

Ornithine Aspartate is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Abdominal discomfort: cramping or bloating. - Diarrhoea: loose stools, usually transient. - Headache: mild tension‑type headache. - Dizziness: occasional light‑headedness. - Taste alteration: metallic or bitter taste.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing. - Hepatic decompensation: worsening liver function in susceptible patients. - Electrolyte imbalance: especially if combined with other ammonia‑lowering agents. - Acute pancreatitis: rare but reported. - Hypotension: sudden drop in blood pressure. - Thrombocytopenia: low platelet count observed in isolated cases.

When prescribing Ornithine Aspartate, clinicians should consider several safety measures.

- Liver function assessment: evaluate baseline hepatic status before initiation. - Ammonia monitoring: regularly check blood ammonia levels to gauge efficacy. - Renal impairment caution: adjust use in patients with severe kidney dysfunction. - Pregnancy and lactation: use only if potential benefit outweighs risk. - Concomitant hepatotoxic drugs: avoid or monitor closely for additive liver stress. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Ornithine Aspartate may interact with other medications that affect ammonia metabolism or liver function.

Major Interactions (Avoid): - Lactulose: combined use can cause excessive electrolyte shifts. - Sodium benzoate: additive ammonia‑lowering effect may lead to overly low ammonia levels. - High‑dose vitamin B6: may potentiate metabolic pathways and alter efficacy.

Moderate Interactions (Monitor Closely): - Diuretics: monitor electrolytes and renal function. - Broad‑spectrum antibiotics: may change gut flora and affect ammonia production. - Alcohol: can exacerbate liver injury and counteract therapeutic benefit.